CGON (CG Oncology) Change In Inventory : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Change In Inventory?

CG Oncology's change in inventory for the quarter that ended in Sep. 2024 was $0.00 Mil. It means CG Oncology's inventory stayed the same from Jun. 2024 to Sep. 2024 .

CG Oncology's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means CG Oncology's inventory stayed the same from Dec. 2022 to Dec. 2023 .

CG Oncology's Total Inventories for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. CG Oncology's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.00.

CG Oncology Change In Inventory Historical Data

The historical data trend for CG Oncology's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Change In Inventory Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Change In Inventory

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Inventory	Get a 7-Day Free Trial					-	-	-	-	-

CG Oncology Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

CG Oncology (NAS:CGON) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CG Oncology's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

CG Oncology's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CG Oncology's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.043
	=	0.00

CG Oncology Change In Inventory Related Terms

Thank you for viewing the detailed overview of CG Oncology's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.